Dr Patel on the FDA Approval of Durvalumab Plus Chemotherapy for NSCLC - OncLive
FDA approved perioperative durvalumab plus neoadjuvant chemotherapy for resectable NSCLC in Aug 2024, based on AEGEAN trial data. This introduces immune checkpoint blockade earlier, potentially increasing cure rates. Key trial outcomes included pathologic complete response and survival, with molecular testing for EGFR/ALK mutations crucial. Patients benefited regardless of PD-L1 status.
Related Clinical Trials
Highlighted Terms
Related News
FDA approved perioperative durvalumab plus neoadjuvant chemotherapy for resectable NSCLC in Aug 2024, based on AEGEAN trial data. This introduces immune checkpoint blockade earlier, potentially increasing cure rates. Key trial outcomes included pathologic complete response and survival, with molecular testing for EGFR/ALK mutations crucial. Patients benefited regardless of PD-L1 status.
The AEGEAN trial's second interim analysis confirmed the safety and efficacy of perioperative durvalumab plus neoadjuvant chemotherapy in resectable NSCLC, showing improved event-free survival, disease-free survival, and a trend toward better overall survival. The regimen had a manageable adverse event profile.